Barclays raised Xeris Biopharma stock target to USD 14.00

Published on 10/08/2026 at 11:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Net product revenue grew 34.00 percent in the second quarter. Xeris Biopharma stock costs EUR 8.96 on October 8, 2026 versus EUR 9.02.

XERS, US98422E1038, Illustration mit AI erstellt.

Xeris Biopharma stock (ISIN US98422E1038) was at EUR 8.96 at Lang & Schwarz on October 8, 2026 at 11:41 a.m. CEST, down 0.67 percent versus the EUR 9.02 prior close. The latest analyst move came from Barclays, which raised its Xeris target from USD 12.00 to USD 14.00 on October 6, 2026.

Barclays lifts the valuation bar

According to Markets Insider on October 6, 2026, Barclays analyst Jenna Davidner kept an Overweight rating while increasing the price target from USD 12.00 to USD 14.00. The note cited the setup ahead of the third-quarter report and progress in the Recorlev and XP-8121 programs.

The target change gives investors a concrete valuation reference, but it does not erase the earnings risk. Xeris reported a USD 0.18 GAAP loss per share for the second quarter of 2026, compared with a USD 0.01 consensus profit, while revenue exceeded the USD 90.12 million estimate at USD 92.10 million, according to MarketBeat on October 5, 2026.

Revenue growth remains the operating anchor

Xeris Biopharma reported USD 91.0 million of net product revenue in the second quarter of 2026, up 34.00 percent from the same quarter of 2025. Recorlev revenue increased 81.00 percent year over year to USD 56.78 million, making it the clearest growth driver in the reported portfolio.

The company also tightened full-year 2026 total revenue guidance to USD 385.0 million to USD 390.0 million. Adjusted EBITDA reached USD 19.3 million in the second quarter of 2026, up from USD 12.5 million in the year-earlier quarter, although the reported net loss widened to USD 31.1 million because of a one-time, non-cash charge of approximately USD 31.0 million tied to the 2028 convertible-note exchange agreements.

Stock remains below its yearly high

The US primary listing is Nasdaq, where Xeris Biopharma trades in USD. The finance quote for October 7, 2026 put market capitalization at USD 1.7 billion and the 52-week range at USD 5.25 to USD 11.33, so the Lang & Schwarz euro quote remains within the corresponding US-dollar valuation corridor after currency conversion.

For investors, the key tension is visible in the numbers: Recorlev is expanding quickly, while the second-quarter loss and the one-time financing charge make earnings quality central to the next report. Barclays' USD 14.00 target is therefore tied to execution across the commercial portfolio and XP-8121, not only to the current revenue trajectory.

EUR 8.96 in midday trading

Xeris Biopharma stock was at EUR 8.96 at Lang & Schwarz on October 8, 2026 at 11:41 a.m. CEST, down 0.67 percent from the EUR 9.02 prior close. The primary Nasdaq listing had a latest finance quote of USD 10.11 dated October 7, 2026 at 4:00 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Xeris Biopharma stock.